Lonza forecasts 2026 sales growth of 11-12% for core CDMO business
28/01/2026 06:16
Repeats story with no changes
Jan 28 - Lonza LONN.S, the world's largest contract drug manufacturer, on Wednesday set 2026 targets for its contract development and manufacturing organization (CDMO) business, expecting sales growth of 11% to 12% at constant exchange rates and core profit margin expansion to above 32% of sales.
The Swiss company added it expected sales growth to be higher in the first half of 2026 than in the second half.
(Reporting by Bernadette Hogg and Orest Dovhan in Gdansk, editing by Milla Nissi-Prussak)
((bernadette.hogg@thomsonreuters.com))
Recent news on Lonza AG
See all newsLonza buys 5 sites from Germany's Merck to more than double US footprint (updated)
Brief: Merck KGaA Confirms Divestment Of CDMO Business To Lonza
Lonza agrees to buy five US sites from Merck KGaA
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September